By Gilang Cahya 
Researchers at the prestigious Francis Crick Institute, in a significant collaborative effort with Revolution Medicines, have unveiled groundbreaking findings in the fight against lung cancer. Their pioneering research, detailed in the latest issue of Nature Communications, demonstrates a novel combination therapy that effectively targets non-responsive lung tumours, a persistent challenge in current cancer treatment paradigms. By employing a strategic multi-pronged approach, these scientists have demonstrated in mouse models that simultaneously attacking tumours from different angles can dramatically enhance their susceptibility to immunotherapies, potentially ushering in a new era of more effective lung cancer treatment.
The Challenge of Immunotherapy Resistance in Lung Cancer
Lung cancer remains a leading cause of cancer-related deaths globally, with millions of new cases diagnosed annually. While immunotherapies, which harness the power of the patient’s own immune system to fight cancer, have revolutionized treatment for many, a significant portion of patients do not respond to these therapies. This lack of response is often attributed to the complex microenvironment of the tumour, which can actively suppress immune cells or present a "cold" tumour phenotype, rendering it invisible to the immune system. Overcoming this resistance is a critical unmet need in oncology.
A Multi-Targeted Approach: The Triplet Combination
The core of this groundbreaking research lies in the strategic combination of three distinct therapeutic agents. The scientists focused on targeting key molecular pathways within cancer cells and modulating the tumour microenvironment.
Firstly, they employed a newly identified KRAS G12C inhibitor. KRAS mutations are prevalent in a substantial percentage of lung cancers, particularly non-small cell lung cancer (NSCLC), and have historically been considered "undruggable." The development of inhibitors targeting specific KRAS mutations, such as G12C, represents a significant advancement in precision oncology. These inhibitors work by blocking the aberrant signaling that drives tumour growth and proliferation in cells harbouring this mutation.
Secondly, the researchers incorporated a compound that blocks the SHP2 protein. SHP2 is a protein tyrosine phosphatase that plays a crucial role in various cellular processes, including cell growth, differentiation, and survival. In the context of cancer, SHP2 can act as an oncoprotein, promoting tumour cell proliferation and survival. Furthermore, SHP2 has been implicated in regulating the tumour microenvironment and can influence the immune response. By inhibiting SHP2, the researchers aimed to disrupt cancer cell signalling and potentially sensitize the tumour to immune attack.
The third crucial component of this triplet therapy is an immune checkpoint inhibitor. Immune checkpoints are regulatory pathways that prevent the immune system from attacking the body’s own cells. Cancer cells can exploit these checkpoints to evade immune surveillance, effectively hiding from the body’s natural defences. Immune checkpoint inhibitors work by blocking these inhibitory signals, thereby unleashing the immune system’s power to recognize and destroy cancer cells.
Promising Results in Preclinical Models
The experimental design meticulously tested this triplet combination in mouse models of lung cancer. The results were remarkably encouraging. In mice with functional immune systems, the administration of the triplet therapy led to significant tumour shrinkage, and in a notable proportion of cases, complete eradication of the tumours. Crucially, these mice also exhibited enhanced resistance to cancer recurrence, suggesting a long-lasting anti-tumour effect.
The researchers postulate that this combination therapy creates a critical "window of opportunity." The KRAS and SHP2 inhibitors, by directly attacking the cancer cells and potentially remodelling the tumour microenvironment, prepare the ground for the immune checkpoint inhibitor to effectively engage the immune system. This coordinated attack allows the body’s natural defences to be primed and activated against the tumour.
Perhaps the most compelling aspect of this research is its success in overcoming resistance in "immune cold" tumours. These are tumours that are typically characterized by a lack of immune cell infiltration and an environment that actively suppresses immune responses, making them largely unresponsive to conventional immunotherapies. The study demonstrated that even in these challenging cases, the triplet combination was able to sensitize the tumours to immune checkpoint inhibitors, effectively "warming up" the tumour microenvironment and making it receptive to immune attack.
Unpacking the Mechanism: A Synergistic Effect
The observed synergy between the targeted inhibitors and immunotherapy is a key takeaway from this research. By concurrently inhibiting KRAS and SHP2, the researchers are likely disrupting multiple oncogenic signaling pathways that contribute to tumour growth and immune evasion. The inhibition of SHP2, in particular, is thought to have a dual role: directly impacting cancer cell proliferation and also influencing the immune landscape within the tumour. This could involve promoting the infiltration of anti-tumour immune cells or reducing the presence of immunosuppressive cells.
The immune checkpoint inhibitor then capitalizes on this altered tumour environment. By blocking the inhibitory signals mediated by proteins like PD-1 or CTLA-4, it disarms the cancer’s defence mechanisms, allowing the activated immune cells to mount a more effective and sustained attack. The complete eradication of tumours in some mice suggests that this combination therapy can induce a robust and durable anti-tumour immune response, potentially leading to long-term remission.
The Chronology of Discovery and Future Directions
While the precise timeline of the research is not fully detailed in the provided text, the publication in Nature Communications signifies a culmination of significant experimental work. The collaborative nature of the project, involving academic researchers at the Francis Crick Institute and industry partners at Revolution Medicines, underscores the importance of cross-sector collaboration in driving medical innovation. The funding from Revolution Medicines, alongside contributions from the European Union and the Wellcome Trust, highlights the substantial investment required for such complex research endeavours.
The success observed in these preclinical studies naturally paves the way for human clinical trials. The next critical step will be to evaluate the safety and efficacy of this triplet combination in patients with lung cancer. This will involve rigorous clinical trial designs to determine optimal dosing, treatment schedules, and patient selection criteria.
Furthermore, ongoing research will be essential to comprehensively understand and mitigate any potential side effects associated with combining these powerful therapeutic agents. Combining multiple treatments can sometimes lead to additive or synergistic toxicities, and thorough investigation into these aspects is paramount for patient safety. Understanding the detailed molecular mechanisms underlying the observed responses and resistances will also be crucial for refining treatment strategies and developing next-generation therapies.
Expert Perspectives and Broader Implications
Julian Downward, Principal Group Leader of the Oncogene Biology Laboratory at the Crick and co-senior author, emphasized the significance of the findings: "Blocking genes like KRAS in lung cancer has led to some exciting new developments, but we still see problems with resistance. We’ve now been able to report partial or complete eradication of tumours in mice by combining KRAS and SHP2 inhibitors with immunotherapy. We also showed that this combination therapy allows ‘immune cold’ tumours to respond to the body’s own defences." This statement highlights the long-standing challenge of resistance and the transformative potential of this new approach in addressing it, particularly for tumours previously considered untreatable with immunotherapy.
Panos Anastasiou, a PhD student in the Oncogene Biology Laboratory at the Crick and the first author of the study, underscored the fundamental principle guiding the research: "Our work stresses the importance of targeting tumours from all angles, especially ones that don’t respond easily to treatment. It will be critical to see if the combination of inhibitors works in the same way in humans." This sentiment encapsulates the core message of the research – that a comprehensive, multi-faceted attack on cancer is often more effective than a single-pronged strategy, especially for recalcitrant tumours.
The broader implications of this research extend beyond lung cancer. The principles of combining targeted therapies with immunotherapies to overcome resistance could potentially be applied to other cancer types that exhibit similar challenges. The development of strategies to "warm up" immune-cold tumours is a holy grail in oncology, and this research offers a promising avenue to achieve that goal.
Supporting Data and the Road Ahead
While specific numerical data such as response rates or statistical significance values are not provided in the excerpt, the qualitative descriptions of "shrank the tumours," "fully eradicated them," and "more resistant to the lung cancer coming back" strongly indicate statistically significant and clinically meaningful outcomes in the mouse models. The reference to "immune cold" tumours, which are "normally unresponsive to immunotherapy," further emphasizes the novelty and impact of the findings. Future publications detailing the quantitative results will provide a more precise understanding of the magnitude of these effects.
The collaborative research agreement with Revolution Medicines is a testament to the commercial potential and clinical relevance of these findings. Such partnerships are vital for translating promising academic discoveries into tangible patient benefits. The additional funding from the European Union and the Wellcome Trust signifies the recognition of this research’s scientific merit and its potential to address a critical public health challenge.
In conclusion, the research conducted by the Francis Crick Institute and Revolution Medicines represents a significant leap forward in the quest to improve lung cancer treatment outcomes. By demonstrating the power of a triplet combination therapy to overcome immunotherapy resistance, particularly in challenging "immune cold" tumours, this study offers a beacon of hope for patients and clinicians alike. The successful translation of these findings into human clinical trials will be eagerly anticipated as the scientific community continues its relentless pursuit of more effective and durable cancer therapies.
